Hopkins said that lenacapavir was expected to be reviewed by the U.S. Food and Drug Administration in 2025, with the potential to dramatically reduce HIV infection. "This will be a critical next step ...
This year we saw more examples of the destructive effort to undermine abortion as a health service. But overreach into health practices was not limited to abortion care.
The firm highlighted that Gilead's shares have seen a rise due to positive developments in its pipeline, particularly for Lenacapavir in HIV prevention and anito-cel in multiple myeloma. Gilead's ...